CAIRO, April 8, 2018 - The Ministry of Health and Population has approved a new drug known as Toujeo (insulin glargine injection 300 Units /mL) which controls the level of glucose in the blood, with little incidence of low sugar episodes. The new medicine is administered once a day. Sanofi, the pharmaceutical company that has produced the new medicine and this kind of insulin, says it is a long-acting medicine that is given once a day to adults affected by diabetes types 1 and 2 and it was available on the market, early this year. Sanofi has a wide experience in producing diabetes medicines and insulin treatments. These include the drug, Lantus, which has helped many patients around the world to control the level of glucose in the blood. "With the approval of the Ministry of Health, Sanofi is looking forward to producing new drugs for the treatment of patients with diabetes," said Dr Hala Ramzi, Director of the company's Medical Sector. She added that constant control of insulin throughout the day was a challenge for all diabetics and caregivers because of the fear of a drop in the level of insulin in the blood. So, Toujeo is a new option to help patients coexist with the disease. Sanofi is an international company specialised in varied health care. Its first pharmaceutical plant was built in 1962 and it has been expanding for 55 years. The company supplies the local market with vaccines, pain-killers and medicines to treat rare diseases. Sanofi employs 1,200 workers and has been awarded a prize as "Top Employer 2018".